Invivyd (NASDAQ:IVVD) Director Kevin Mclaughlin Buys 50,000 Shares of Stock

Invivyd, Inc. (NASDAQ:IVVD) Director Kevin Mclaughlin acquired 50,000 shares of the firm’s stock in a transaction on Wednesday, November 19th. The shares were bought at an average cost of $2.50 per share, for a total transaction of $125,000.00. Following the acquisition, the director owned 50,000 shares in the company, valued at approximately $125,000. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Invivyd Stock Performance

Shares of NASDAQ IVVD traded up $0.10 during trading on Friday, reaching $2.50. The company had a trading volume of 1,510,095 shares, compared to its average volume of 7,942,099. Invivyd, Inc. has a 52 week low of $0.35 and a 52 week high of $3.07. The business’s 50 day moving average price is $1.67 and its 200-day moving average price is $1.10. The stock has a market cap of $581.63 million, a PE ratio of -5.31 and a beta of 0.64.

Invivyd (NASDAQ:IVVD) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.06) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.01). The company had revenue of $13.13 million during the quarter, compared to the consensus estimate of $12.00 million. Invivyd had a negative return on equity of 92.97% and a negative net margin of 119.63%. Equities analysts anticipate that Invivyd, Inc. will post -1.64 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in IVVD. Catalyst Funds Management Pty Ltd bought a new stake in shares of Invivyd in the second quarter valued at about $27,000. Vanguard Personalized Indexing Management LLC boosted its position in Invivyd by 238.6% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 39,941 shares of the company’s stock worth $29,000 after acquiring an additional 28,146 shares during the last quarter. Bank of America Corp DE raised its holdings in shares of Invivyd by 330.5% in the third quarter. Bank of America Corp DE now owns 49,252 shares of the company’s stock valued at $54,000 after purchasing an additional 37,811 shares during the last quarter. Nuveen LLC bought a new position in Invivyd in the first quarter valued at $65,000. Finally, XTX Topco Ltd acquired a new stake in Invivyd in the 1st quarter valued at $66,000. Institutional investors and hedge funds own 70.36% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on IVVD. Weiss Ratings reissued a “sell (e+)” rating on shares of Invivyd in a report on Friday, October 31st. Cantor Fitzgerald initiated coverage on Invivyd in a research note on Monday, October 6th. They set an “overweight” rating and a $10.00 price objective for the company. Zacks Research upgraded Invivyd from a “strong sell” rating to a “hold” rating in a report on Thursday, November 13th. D. Boral Capital increased their price target on shares of Invivyd from $1.00 to $2.00 and gave the company a “buy” rating in a research report on Monday, October 6th. Finally, HC Wainwright lifted their price objective on shares of Invivyd from $5.00 to $10.00 and gave the stock a “buy” rating in a research note on Friday, October 31st. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Invivyd has a consensus rating of “Hold” and an average price target of $7.33.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.